About: Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
Creator	Chen, Zhiwei Zhang, Linqi Ba, Lei Ho, David Yi, Christopher
Source	Medline; PMC
abstract	Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection.
has issue date	2007-06-21(xsd:dateTime)
bibo:doi	10.1007/s00253-007-1073-y
bibo:pmid	17581748
has license	no-cc
sha1sum (hex)	7e46ae0414399709f36d00a9bff2ec3b362784bf
schema:url	https://doi.org/10.1007/s00253-007-1073-y
resource representing a document's title	Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
has PubMed Central identifier	PMC7079952
has PubMed identifier	17581748
schema:publication	Appl Microbiol Biotechnol
resource representing a document's body	covid:7e46ae0414399709f36d00a9bff2ec3b362784bf#body_text
is schema:about of	named entity 'played' named entity 'initial' named entity 'neutralizing antibody' named entity 'REMAINS' named entity 'HETEROLOGOUS' named entity 'SARS CORONAVIRUS' named entity 'HUMANS' named entity 'SARS-COV' named entity 'NAB' named entity 'VACCINATION' named entity 'USING' named entity 'REQUIRED' named entity 'VACCINES' named entity 'COMPARED' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'UNKNOWN' named entity 'ANKARA' named entity 'VACCINATED' named entity 'REGIMENS' named entity 'INDUCE' named entity 'HAVE' named entity 'SECONDARY' named entity 'PLAYED' named entity 'CHINESE' named entity 'DATE' named entity 'OUR' named entity 'STERILE' named entity 'HIGHEST' named entity 'PRIME' named entity 'REGIMEN' named entity 'PERSISTENT' named entity 'VACCINE' named entity 'IN VIVO' named entity 'VARIOUS' named entity 'PROVIDES' named entity 'PRIME' named entity 'VACCINE DEVELOPMENT' named entity 'HERE' named entity 'STUDIES' named entity 'PERSISTENT' named entity 'ADENOVIRUS TYPE 5' named entity 'PREVIOUS' named entity '28S' named entity 'AD5' named entity 'MVA' named entity 'PREDICT' named entity 'NEUTRALIZING ANTIBODY' named entity 'REGIMEN' named entity 'HETEROLOGOUS' named entity 'CAUSED BY' named entity 'INITIAL' named entity 'HIGH' named entity 'AD5' named entity 'MICE' named entity 'TECHNIQUES' named entity 'MINIMAL' named entity 'DNA' named entity 'MODIFIED' named entity 'IMMUNITY' named entity 'MVA' named entity 'NEUTRALIZING ANTIBODY' named entity 'BOOST' named entity 'EVALUATE' named entity 'OPTIMAL' named entity 'COMBINATIONS' named entity 'RESPONSE' named entity 'BOOST' named entity 'CRITICAL' named entity 'STRONG' named entity 'SPIKE' named entity 'IMPORTANT' named entity 'ANTIBODY RESPONSE' named entity 'LEVELS' named entity 'ROLE' named entity 'CHALLENGE' named entity 'RHESUS MONKEYS' named entity 'PROTECTING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software